Chris Storgard

Chris Storgard currently serves as the Chief Medical Officer at Design Therapeutics, a position held since April 2025. Previously, Chris held the same title at ADARx Pharmaceuticals Inc. from April 2024 to March 2025, at Heron Therapeutics, Inc. from November 2018 to March 2024, and at Fate Therapeutics Inc. from June 2016 to November 2018, focusing on the clinical development of cellular immunotherapies. Earlier roles include Vice President of Clinical Research and Development at Ardea Biosciences, where Chris led the global clinical program for Zurampic, and served as Executive Director, overseeing Phase 3 trials for lesinurad. Chris completed medical education with a Doctor of Medicine degree from the University of Saskatchewan and a Rheumatology fellowship at Scripps Clinic and Research Center.